ArticleGut2003
Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study.
Article in Gut, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05703425 (The Effect of Sulfasalazine on CRH Levels in Pregnant Women With a History of Pre-Term Birth), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Sulfasalazine on CRH Levels in Pregnant Women With a History of Pre-Term Birth: A Randomized Controlled Trial
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Inflammatory Bowel Disease Increases Risk of Adverse Pregnancy Outcomes: A Meta-Analysis.Digestive diseases and sciences · 2015Pooled it
- Pooled it
- Guideline
- Management of Pregnancy in Women with Inflammatory Bowel Disease: Positioning Janus Kinase Inhibitors Within Current Evidence.Current issues in molecular biology · 2026Review
- Navigating Reproductive Care in Patients With Inflammatory Bowel Disease: A Comprehensive Review.Journal of Crohn's & colitis · 2024Review
- Inflammatory bowel disease in pregnancy and breastfeeding.Nature reviews. Gastroenterology & hepatology · 2023Review
- The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study.Alimentary pharmacology & therapeutics · 2022Article
- Pregnancy and medications in inflammatory bowel disease.Obstetric medicine · 2021Review
- Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations.Nature reviews. Neurology · 2020Review
- Managing IBD Therapies in Pregnancy.Current treatment options in gastroenterology · 2017Review
- Treatment of pregnant women with a diagnosis of inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2016Review
- Managing inflammatory bowel disease in pregnancy: current perspectives.Clinical and experimental gastroenterology · 2016Review
- Urinary phthalate metabolite concentrations among men with inflammatory bowel disease on mesalamine therapy.Endocrine disruptors (Austin, Tex.) · 2014Article
- Presence of phthalates in gastrointestinal medications: is there a hidden danger?World journal of gastroenterology · 2013Review
- Crohn's disease in women.International journal of women's health · 2013Review
- Pregnancy related issues in inflammatory bowel disease: evidence base and patients' perspective.World journal of gastroenterology · 2012Review
- A complicated case of tacrolimus-induced rapid remission after cesarean section in the early third trimester for refractory severe ulcerative colitis flaring in the initial period of gestation.Case reports in gastroenterology · 2011Article
- Pros and cons of medical management of ulcerative colitis.Clinics in colon and rectal surgery · 2010Article
- Pregnancy in glycogen storage disease type Ib: gestational care and report of first successful deliveries.Journal of inherited metabolic disease · 2010Article
- Management of inflammatory bowel disease in pregnancy.Obstetric medicine · 2010Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background5-Aminosalicylic acid (5-ASA) preparations are the firstline drugs in the treatment of inflammatory bowel disease. Data on the safety of these drugs in pregnancy are sparse.
aimsTo examine the risk of adverse birth outcome in women who were prescribed 5-ASA drugs during pregnancy. PATIENTS: Women were included in the study if they were prescribed 5-ASA drugs immediately before or during pregnancy. To examine the risk of malformations, we included 60 pregnancies exposed to 5-ASA drugs 30 days before pregnancy or in the first trimester. To examine stillbirths, preterm births, and low birth weight, we included 88 pregnancies exposed during the entire pregnancy. Outcomes were compared with those of 19 418 pregnancies in which no drugs were prescribed for mothers during the study period.
methodsWe conducted a Danish cohort study based on data from a population based prescription registry, the Danish Birth Registry, and the Hospital Discharge Registry in North Jutland County.
resultsOdds ratios for malformations, stillbirth, preterm birth, and low birth weight in women who received prescriptions for 5-ASA drugs were 1.9 (95% confidence interval 0.7-5.4), 6.4 (1.7-24.9), 1.9 (0.9-3.9), and 1.2 (0.4-3.3), respectively. The increased risk of stillbirth and preterm birth were found only in patients with ulcerative colitis.
conclusionsWe found an increased risk of stillbirth and preterm birth in women who had been prescribed 5-ASA drugs during pregnancy but no substantial increased risk of malformations. It was difficult to distinguish the specific effects of disease activity and 5-ASA drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.